China NMPA Medical Device Registration Services for Foreign Manufacturers
Trusted services for Medical Device and IVD manufacturers seeking NMPA Registration and China Market Access.
Navigating China’s Medical Device Regulatory Landscape
Navigating China’s Medical Device Regulatory Landscape
Entering China's medical device market requires navigating one of the world's most demanding regulatory frameworks. To sell a medical device in China, manufacturers must meet the NMPA's rigorous end-to-end compliance requirements before entering the market. For foreign manufacturers, additional barriers, such as language and coordination with local Chinese authorities, pose a significant risk of delays and cost overruns.
Our NMPA registration consultants combine deep global regulatory expertise with local China market knowledge to help medical device and IVD manufacturers achieve faster, more reliable NMPA approval.
How Our China NMPA Consultants Support Your Market Access
We support manufacturers across every stage of the NMPA registration process, from initial regulatory strategy through dossier submission and long-term post-market compliance. Our team builds a tailored pathway to China market approval.
Our China NMPA Medical Device Registration Services:
China Regulatory Strategy & Product
We determine your device's correct NMPA classification — Class I, II, or III — and define the most efficient regulatory pathway, including assessment of applicable Chinese national standards (YY standards) and registration requirements under the 2021 NMPA Medical Device Supervision and Administration Regulations.
NMPA Registration Dossier Preparation
We compile and prepare a complete NMPA registration dossier fully aligned with Chinese regulatory requirements.
Type Testing Coordination
We coordinate mandatory type testing with CNAS-accredited Chinese laboratories and compliance with standards to keep your timeline on track.
Clinical Evaluation & Clinical Trial Support
We develop clinical evaluation strategies leveraging equivalent device data, post-market clinical follow-up where eligible, and coordinate China-based clinical trials when required by the NMPA.
Local Agent Representation
Foreign manufacturers are legally required to appoint a qualified local agent in China. We provide this service, acting as your regulatory liaison with the NMPA and serving as the official contact for all post-market regulatory obligations.
Submission Management & Authority Communication
We manage your dossier submission to the NMPA's Center for Medical Device Evaluation (CMDE) and support all correspondence, queries, and deficiency responses during the technical review process.
Post-Market Regulatory Compliance
We support ongoing obligations, including registration certificate renewals (every 5 years), product change applications, adverse event reporting, and compliance with the 2022 NMPA post-market surveillance requirements.
Step-by-Step China NMPA Registration Process
Step 1 — Product Classification & Regulatory Assessment: We assess your device using the NMPA's classification catalogue and relevant technical guidelines to determine Class I, II, or III status and identify applicable standards.
Step 2 — Registration Strategy Development We build a regulatory roadmap that covers type testing scope, clinical evaluation strategy, documentation requirements, and realistic submission timelines — typically 12–24 months for Class II/III devices.
Step 3 — Type Testing & Technical Documentation We coordinate testing at certified Chinese laboratories and prepare your technical file — including product descriptions, design verification, risk management, and labeling — in Chinese and English.
Step 4 — Registration Dossier Compilation We compile and review the full registration dossier to ensure it is complete, accurate, and compliant with NMPA requirements before submission.
Step 5 — NMPA Submission & Review Support We submit your dossier to the NMPA/CMDE and actively manage the review process, responding to technical queries and deficiency notices to prevent unnecessary delays.
Step 6 — Approval & Lifecycle Compliance Post-approval We support registration maintenance, certificate renewals, product modifications, and ongoing compliance with China's post-market regulatory framework.
Step-by-Step China NMPA Registration Process
Step 1 — Product Classification & Regulatory Assessment: We assess your device using the NMPA's classification catalogue and relevant technical guidelines to determine Class I, II, or III status and identify applicable standards.
Step 2 — Registration Strategy Development We build a regulatory roadmap that covers type testing scope, clinical evaluation strategy, documentation requirements, and realistic submission timelines — typically 12–24 months for Class II/III devices.
Step 3 — Type Testing & Technical Documentation We coordinate testing at certified Chinese laboratories and prepare your technical file — including product descriptions, design verification, risk management, and labeling — in Chinese and English.
Step 4 — Registration Dossier Compilation We compile and review the full registration dossier to ensure it is complete, accurate, and compliant with NMPA requirements before submission.
Step 5 — NMPA Submission & Review Support We submit your dossier to the NMPA/CMDE and actively manage the review process, responding to technical queries and deficiency notices to prevent unnecessary delays.
Step 6 — Approval & Lifecycle Compliance Post-approval We support registration maintenance, certificate renewals, product modifications, and ongoing compliance with China's post-market regulatory framework.
Avoid costly delays in China NMPA registration
Avoid costly delays in China NMPA registration
NMPA registration failures most commonly stem from incorrect device classification, non-compliant type testing, incomplete dossier submissions, and poor communication with Chinese authorities. Each of these issues can add 6–12 months to your timeline and a high cost to your market entry budget.
Our China regulatory consultants apply a proactive, structured approach — aligning classification, testing, documentation, and submission strategy from day one — so manufacturers enter the NMPA review process with confidence and exit it efficiently.
Relevant Blogs
Discover how to navigate China's evolving medical device regulations. Learn key steps for NMPA approval, dossier prep, and market access with our guidance.
Discover how to navigate China's evolving medical device regulations with expert guidance. From NMPA approval to dossier preparation and market access.
Understand the China NMPA inspection process, including pre-inspection, on-site, and post-inspection phases, and how foreign manufacturers can prepare.
Still have questions? We are here to help!
How long does it take for China's NMPA to register a medical device?
NMPA registration timelines depend on device classification and the scope of required testing.
- Class II medical devices typically take 12–18 months.
- Class III devices, including implantables and life-supporting devices, commonly require 18–24 months or longer.
- IVD registration timelines vary similarly by risk class. Incomplete dossiers or failed type testing are the most common causes of avoidable delays.
Do foreign manufacturers need a local agent in China?
Yes. Under China's Medical Device Supervision and Administration Regulations (2021), all foreign manufacturers must appoint a qualified local agent in China before applying for NMPA registration. The local agent is legally responsible for liaising with the NMPA, handling post-market regulatory obligations, and serving as the point of contact for adverse event reporting and product recalls.
Is clinical testing always required for NMPA registration?
Not always. Some devices qualify for clinical evaluation based on equivalent device data, published clinical literature, or exemption under the NMPA's clinical evaluation exemption catalogue. Devices in higher-risk categories typically require clinical trials conducted in China and approved by the NMPA.
Can CE marking or FDA clearance be used to support NMPA registration?
Existing FDA or CE marking approvals can provide supporting documentation, but they do not substitute for Chinese regulatory requirements. Mandatory local type testing, China-specific labeling, Chinese-language documentation, and NMPA-formatted dossiers are required regardless of existing international approvals.
What is the difference between NMPA Class II and Class III registration?
Class II medical devices pose a moderate risk and follow a provincial or national NMPA registration pathway with a lower clinical evidence burden. Class III devices present a higher risk and require national NMPA review by the CMDE, more extensive clinical evidence, and stricter manufacturing quality standards.
Does NMPA registration cover IVD products?
Yes. In vitro diagnostics (IVDs) are regulated under the same NMPA framework and classified as Class I, II, or III based on risk. IVD registration has specific requirements for analytical performance testing, reference materials, and clinical performance studies that differ from those for general medical devices.